Mark Denison

VUMC team aids development of potential antiviral drug for COVID-19

Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

Denison named director of Pediatric Infectious Diseases

Mark Denison, MD, has been named director of the Division of Pediatric Infectious Diseases in the Vanderbilt Department of Pediatrics.

Team investigates antiviral that inhibits SARS, MERS

A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.

Medical societies honor four VUMC physicians

Four physicians from Vanderbilt University Medical Center (VUMC) have been elected to membership in two of the nation’s oldest and most respected medical honor societies — the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI).

Pediatrics awarded physician-scientist training support

The National Institutes of Health (NIH) has awarded Vanderbilt’s Department of Pediatrics a K12 training grant to support early career faculty to become physician-scientists, the first time the department has received such an award.

Contributors to coronavirus ‘fitness’

Understanding the role that host membrane modification plays in coronavirus replication is essential for developing novel approaches to block the viruses that cause SARS and MERS.

1 2